Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Capital Expenditures (2022 - 2025)

Historic Capital Expenditures for Day One Biopharmaceuticals (DAWN) over the last 4 years, with Q2 2025 value amounting to -$1.7 million.

  • Day One Biopharmaceuticals' Capital Expenditures fell 10305.45% to -$1.7 million in Q2 2025 from the same period last year, while for Sep 2025 it was $19.6 million, marking a year-over-year increase of 248179.42%. This contributed to the annual value of $20.0 million for FY2024, which is 882857.14% up from last year.
  • As of Q2 2025, Day One Biopharmaceuticals' Capital Expenditures stood at -$1.7 million, which was down 10305.45% from $2.0 million recorded in Q1 2025.
  • In the past 5 years, Day One Biopharmaceuticals' Capital Expenditures registered a high of $55.0 million during Q2 2024, and its lowest value of -$54.2 million during Q3 2024.
  • Its 4-year average for Capital Expenditures is $1.7 million, with a median of $20500.0 in 2022.
  • Examining YoY changes over the last 5 years, Day One Biopharmaceuticals' Capital Expenditures showed a top increase of 24052500.0% in 2024 and a maximum decrease of 13241707.32% in 2024.
  • Quarter analysis of 4 years shows Day One Biopharmaceuticals' Capital Expenditures stood at $4000.0 in 2022, then surged by 100.0% to $8000.0 in 2023, then surged by 240525.0% to $19.2 million in 2024, then plummeted by 108.73% to -$1.7 million in 2025.
  • Its Capital Expenditures was -$1.7 million in Q2 2025, compared to $2.0 million in Q1 2025 and $19.2 million in Q4 2024.